<DOC>
	<DOCNO>NCT00706147</DOCNO>
	<brief_summary>The purpose study demonstrate safety , tolerability , efficacy arimoclomol subject SOD1 positive familial Amyotrophic Lateral Sclerosis ( ALS ) . This type ALS HEREDITARY ( run family ) , least one person family must ALS . Study hypotheses : Arimoclomol , take dose 200 mg three time daily improve survival defined time death , tracheostomy permanent assist ventilation . In addition , safe well tolerated subject SOD1 positive familial ALS . Funding Source - FDA-OOPD</brief_summary>
	<brief_title>Phase II/III Randomized , Placebo-controlled Trial Arimoclomol SOD1 Positive Familial Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Using seamless , adaptive , phase II/III design , investigator determine safety efficacy arimoclomol patient SOD1 positive familial ALS . Both stage-1 stage-2 randomize , double-blind placebo-controlled population patient rapidly progressive SOD1 positive familial ALS . Patients ALS , history relative affected ALS ( i.e . familial ALS ) presence demonstrable mutation SOD1 gene know associate rapidly progressive disease , eligible inclusion study . Potentially eligible subject undergo screen via telephone , necessary , review outside medical record . The intervention continue 12 month . In event participant reach study endpoint ( e.g . tracheostomy permanently assist ventilation ) study drug terminate . Subjects meet eligibility criterion travel study site final eligibility determination , baseline evaluation randomize 1:1 receive either placebo arimoclomol dose 200 mg t.i.d . Participants evaluate person study site Month-2 . Subsequent telephonic evaluation Month-3 , -4 , -5 , -6 , -8 , -10 perform participant ' home . Safety tolerability evaluation perform visit . Collection blood sample safety laboratory analyse measurement blood pressure , heart rate , respiratory rate , temperature weight perform Months -1 , -3 , -5 , -6 , -8 , -10 participant 's home representative medical monitoring company . A study coordinator may perform in-person visit Month-12 , visit may occur telephonically . A final evaluation perform via telephone Month -13 ( 30 day last dose study medication ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Type ALS hereditary ( runs family ) . El Escorial criterion familial ALS family history pathogenic mutation gene know associated ALS , SOD1 gene . Willingness undergo genetic testing learn result . Demonstrable mutation SOD1 gene report associated rapid rate disease progression ( i.e . A4V , A4T , C6F , C6G , V7E , L8Q , G10V , G41S , H43R , H48Q , D90V , G93A , D101H , D101Y , L106V , I112M , I112T , R115G , L126X , G127X , A145T , V148G , V148I ) possibly associate rapidly progressive disease ( E21G , G37R , L38V , D76Y , L84F , L84V , N86S , D90A het , G93R , I104F , I113T , L144F , L144S ) . Age 18 year old ; male female . Capable provide informed consent comply trial procedure . Diagnosis within less 9 month anticipate date baseline visit AND study participant ' subjective evaluation expect physical condition permit travel study site baseline 2month study visit . Women must able become pregnant ( e.g . post menopausal least one year , surgically sterile , practice adequate birth control method ) duration study . Adequate contraception include : oral contraception , implanted contraception , intrauterine device place least 3 month , barrier method conjunction spermicide . Women childbearing potential must negative pregnancy test screen visit nonlactating . Willing remain stable dose Riluzole remain Riluzole duration trial . Identifiable local medical doctor assist urgent care medical complication may arise . Absence exclusion criterion . History known sensitivity intolerability Arimoclomol relate compound . Exposure investigational drug within 30 day screen visit . Presence follow clinical condition : Substance abuse within past year . Unstable cardiac , pulmonary , renal , hepatic , endocrine , hematologic , active infectious disease . AIDS AIDSrelated complex . Unstable psychiatric illness define psychosis ( hallucination delusion ) , untreated major depression within 90 day screen visit . Positive pregnancy test screen visit . Screening laboratory value : Creatinine great 1.5 . Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) . great 3.0 time upper limit normal . Total bilirubin great 2.0 time upper limit normal . White blood cell ( WBC ) count less 3,500/mm3 . Platelet concentration less 100,000/ul . Hematocrit level le 33 female less 35 male . Female patient breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Hereditary ALS</keyword>
	<keyword>Hereditary neurological disease</keyword>
	<keyword>Lou Gehrig 's Disease</keyword>
	<keyword>Motor Neuron Disease</keyword>
	<keyword>Amyotrophic Lateral Sclerosis ( ALS )</keyword>
	<keyword>Familial ALS</keyword>
	<keyword>Neuromuscular disease</keyword>
	<keyword>SOD1 mutation</keyword>
	<keyword>Superoxide dismutase</keyword>
	<keyword>SOD1 positive ALS</keyword>
	<keyword>inherit ALS</keyword>
</DOC>